Payment overview · 2025
General Payments
$105,052.83
263 reported records · 19 companies
Healthcare provider profile · identity verified
Marc A Tribble, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DALLAS, TX · NPI 1982669883
Verified facts
What the public records show
CMS Open Payments records show Marc A Tribble, M.D. received $105,052.83 in general payments during 2025 across 263 reported records.
ViiV Healthcare Company accounted for 80.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Dovato, Mounjaro, Ozempic, Rukobia, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xyosted by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 286 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $84,276.77 | 80.2% | 147 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $12,937.85 | 12.3% | 49 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $6,444.26 | 6.1% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $271.89 | 0.3% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $244.33 | 0.2% | 10 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $183.94 | 0.2% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $136.32 | 0.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $106.25 | 0.1% | 4 | 2025 |
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $86.86 | 0.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.82 | 0.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $78.74 | 0.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.98 | 0.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.46 | 0.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.95 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.13 | 0.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $19.06 | 0.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.79 | 0.0% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.59 | 0.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $13.84 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $79,705.00 | 28 |
| Travel and Lodging | $12,414.62 | 38 |
| Food and Beverage | $6,848.21 | 195 |
| Honoraria | $6,085.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $51,444.55 | 55 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $28,248.93 | 39 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $11,871.83 | 13 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $6,444.26 | 7 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $373.30 | 18 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $239.03 | 9 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $154.13 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $148.97 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $136.32 | 4 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $121.86 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $106.25 | 4 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $100.55 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $95.36 | 7 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $95.00 | 3 | 2025 |
Source payment records
|
|||||
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $86.86 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $78.74 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $68.86 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.49 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.33 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $42.33 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.63 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $34.27 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 239 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 286 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RUKOBIA rukobia |
2025 | Rukobia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
239 | 30 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
95 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
286 | 41 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Dovato | Dolutegravir Sodium/Lamivudine | 286 | 41 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 239 | 30 |
| Atorvastatin Calcium | Atorvastatin Calcium | 162 | 48 |
| Tivicay | Dolutegravir Sodium | 135 | 15 |
| Alprazolam | Alprazolam | 113 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 37 |
| Descovy | Emtricitabine/Tenofov Alafenam | 95 | 15 |
| Losartan Potassium | Losartan Potassium | 95 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 84 | 26 |
| Lisinopril | Lisinopril | 84 | 25 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 80 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 18 |
| Prezcobix | Darunavir/Cobicistat | 74 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 70 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 69 | 12 |
| Acyclovir | Acyclovir | 66 | 13 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 64 | suppressed |
| Metformin Hcl | Metformin Hcl | 62 | 21 |
| Clonazepam | Clonazepam | 59 | 11 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 57 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 17 |
| Valacyclovir | Valacyclovir Hcl | 56 | 21 |
| Testosterone | Testosterone | 54 | 11 |
| Gabapentin | Gabapentin | 51 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | suppressed |
| Omeprazole | Omeprazole | 50 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 13 |
| Ozempic | Semaglutide | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 12 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 34 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 16 |
| Famotidine | Famotidine | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Egrifta Sv | Tesamorelin Acetate | 19 | suppressed |
| Efavirenz | Efavirenz | 17 | suppressed |
| Isentress Hd | Raltegravir Potassium | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Xyosted | Testosterone Enanthate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Maraviroc | Maraviroc | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $105,052.83 · 263 records | ViiV Healthcare Company | ABRYSVO, AIRSUPRA, APRETUDE, AREXVY, Biktarvy, CABENUVA, CAPLYTA, CAPVAXIVE, COMIRNATY, DOVATO, EGRIFTA, Epclusa, FREESTYLE LIBRE 3, JATENZO, MAVYRET, MOUNJARO, Mytesi, Ozempic, PIFELTRO, PREVNAR 20, REXULTI, RUKOBIA, SHINGRIX, TROGARZO, Tlando, VRAYLAR, Wegovy, XYOSTED, Yeztugo, ZAVZPRET, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error